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The neuregulin/ErbB signaling network is genetically associated
with schizophrenia and modulates hippocampal γ oscillations—
a type of neuronal network activity important for higher brain
processes and altered in psychiatric disorders. Because neuregu-
lin-1 (NRG-1) dramatically increases extracellular dopamine levels
in the hippocampus, we investigated the relationship between
NRG/ErbB and dopamine signaling in hippocampal γ oscillations.
Using agonists for different D1- and D2-type dopamine receptors,
we found that the D4 receptor (D4R) agonist PD168077, but not
D1/D5 and D2/D3 agonists, increases γ oscillation power, and its
effect is blocked by the highly speciﬁc D4R antagonist L-745,870.
Using double in situ hybridization and immunoﬂuorescence histo-
chemistry, we show that hippocampal D4R mRNA and protein are
more highly expressed in GAD67-positive GABAergic interneurons,
many of which express the NRG-1 receptor ErbB4. Importantly, D4
and ErbB4 receptors are coexpressed in parvalbumin-positive bas-
ket cells that are critical for γ oscillations. Last, we report that D4R
activation is essential for the effects of NRG-1 on network activity
because L-745,870 and the atypical antipsychotic clozapine dramati-
cally reduce the NRG-1–induced increase in γ oscillation power. This
unique link between D4R and ErbB4 signaling on γ oscillation power,
and their coexpression in parvalbumin-expressing interneurons,
suggests a cellular mechanism that may be compromised in different
psychiatric disorders affecting cognitive control. These ﬁndings are
important given the association of a DRD4 polymorphism with alter-
ations in attention, working memory, and γ oscillations, and suggest
potential beneﬁts of D4R modulators for targeting cognitive deﬁcits.
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Gamma oscillations (30–80 Hz) are rhythmic local ﬁeldpotentials that synchronize local circuit activity and play an
important role in higher brain processes, such as learning, mem-
ory, and cognition. Impairments in general synchronized network
activity, in particular γ oscillations, are core features of several
neurological and psychiatric disorders, such as schizophrenia, in
which perception, cognition, and working memory are affected (1,
2). γ oscillation power is impaired during cognitive tasks in ﬁrst-
episode schizophrenia independent of medication, indicating that
these alterations are independent of disease history (3).
Pharmacological studies in anesthetized rats and genetic
studies in mutant mice emphasize the importance of recurrent
excitatory and inhibitory interactions for the generation of γ
oscillations in hippocampal networks (4). The development of
methodologies to study neural network activity in acute hippo-
campal slices in vitro, whereby γ oscillations are induced by the
activation of metabotropic glutamate receptors (5), muscarinic
acetylcholine receptors (6), or kainate (KA) receptors (7), has
been instrumental to identify cellular and molecular mechanisms
underlying the generation and regulation of γ oscillations (8, 9).
In particular, bistratiﬁed cells and fast-spiking parvalbumin-
positive (PV+) GABAergic interneurons have been implicated
in the generation of γ oscillations in area CA3 of the hippo-
campus and in the cortex (10). Targeted ablation of α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and
N-methyl-D-aspartate (NMDA) receptors selectively in PV+
interneurons impairs hippocampal network synchrony and results
in deﬁcits in spatial and working memory (11, 12). Consistent with
these ﬁndings, optogenetic activation of PV+ interneurons is
sufﬁcient to modulate γ oscillations, cortical circuit synchrony,
and behaviors (13, 14).
Although it has long been appreciated that dopamine (DA)
inﬂuences processes underlying attention, cognitive salience, and
working memory (15), and that DA levels are altered in schizo-
phrenia, relatively little is known about the effects of DA on γ
oscillation activity in the hippocampus and frontal cortex. The
rodent frontal cortex and hippocampus receive sparse dopami-
nergic innervation from the ventral tegmental area that regulates
synaptic transmission and plasticity (16). We recently found that
signaling via neuregulin-1 (NRG-1) and its cognate trans-
membrane receptor ErbB4, both genetically associated with in-
creased risk for schizophrenia (17), dramatically increases
extracellular DA levels and regulates hippocampal synaptic
plasticity via DA D4 receptor (D4R) activation (18). We also
reported that NRG-1/ErbB4 signaling greatly augments the
power of KA-induced γ oscillations in acute hippocampal slices
(19). Ablation of ErbB4, which is expressed in rodent and pri-
mate hippocampal (19, 20) and cortical (21) GABAergic inter-
neurons (including PV+ interneurons), blocks the effects of
NRG-1 and reduces γ oscillation power by more than 50% (19).
Taken together, these ﬁndings suggested a potential interaction
between the NRG-1/ErbB4 and DA signaling pathways in the
regulation of γ oscillations in the hippocampus. Therefore, in
the present study we have investigated the role of DA receptor
subtypes (D1–D5), as well as their interaction with the NRG-1/
ErbB4 signaling pathway, in regulating KA-induced γ oscillations.
Results
D1- and D2-Type Receptor Expression in the Hippocampus. Using
sensitive semiquantitative reverse transcription PCR (qRT-PCR)
to compare the relative mRNA levels of D1–D5 receptors in the
frontal cortex and the hippocampus, we found that DA receptor
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subtypes are vastly different (Fig. S1). In the hippocampus, D2-
type DA receptor transcript levels are 10- to 1,000-fold lower
than D1-type receptor mRNAs (D1/β-actin: 2.4 ± 0.72E-03;
D5/β-actin: 7.5 ± 2.0E-03). Among the D2-type DA receptors,
D2 is the most abundant, (D2/β-actin: 7.0 ± 1.4E-04), followed
by D4 (D4/β-actin: 4.1 ± 0.6E-05). Transcripts for D3 are ex-
tremely low (D3/β-actin: 2.0 ± 1.0E-06).
Effects of DA Receptor Subtype Activation on KA-Induced γ Oscillations.
D1-type and D2-type DA receptors are positively and negatively
coupled to adenylate cyclase, respectively, and frequently mediate
opposing effects on distinct functions in the cortex (22, 23) and
hippocampus (16, 17). To investigate the effects of DA on hip-
pocampal network activity, γ oscillations were induced with 100
nM KA, and slices were then perfused with either 10 nM, 10 μM,
or 200 μM DA. No signiﬁcant increase of γ oscillation power was
observed at these DA concentrations (Fig. 1 A and E and Table
S1). Next, we pharmacologically dissected the possible in-
volvement of D1- and D2-type receptor subtypes. When DA was
added to slices treated with KA and the selective D1-type receptor
antagonist SCH23390 (300 nM), γ oscillation power increased
from 1.99E-09 ± 9.32E-10 V2 to 2.56E-09 ± 1.08E-09 V2 (n = 7, P
= 0.0313) without effects on peak frequency (Fig. 1B); normalized
γ power increased to 141.19% ± 15.37% (Fig. 1E). This result
suggested that an effect of DA on γ oscillations mediated through
D2-type receptors could be unmasked by blocking D1-type
receptors. To further identify the speciﬁc DA receptor subtype(s)
capable of modulating γ oscillations, we used selective agonists for
D1/D5 and D2/D3 receptors. As shown in representative traces
and power spectra (Fig. 1C), perfusion of hippocampal slices with
the D1/D5 receptor-selective agonist SKF81297 (1 μM) affected
neither frequency nor amplitude of γ oscillations (KA: 3.36E-09 ±
9.51E-10 V2 vs. KA+SKF81297: 3.93E-09 ± 1.40E-09 V2; n = 14,
P = 0.5016). Next, slices were perfused with 7-hydroxy-DPAT (7-
OH-DPAT; 100 nM), a selective D2/D3 receptor agonist. As
shown in Fig. 1 D and E, 7-OH-DPAT had no signiﬁcant effect on
KA-induced γ oscillation power (KA: 8.26E-09 ± 2.34E-09 V2 vs.
KA+7-OH-DPAT: 1.33E-08 ± 2.35E-09 V2; n = 10, P = 0.23).
D4R Activation Augments KA-Induced γ Oscillations. In contrast to
the D1/D5 and D2/D3 receptor agonists, the D4R selective ag-
onist PD168077 (100 nM) signiﬁcantly augmented normalized γ
oscillation power to 140.65% ± 9.86% (KA: 5.11E-09 ± 1.88E-
09 V2 vs. KA+PD168077: 8.53E-09 ± 3.99E-09 V2; n = 13, P =
0.0024; Fig. 2 A and D) without affecting oscillation peak fre-
quency (KA: 32.07 ± 1.24 Hz vs. KA+PD168077: 30.80 ± 1.07
Hz; n = 13, paired t test, P = 0.1751). No activity pattern was
either generated or changed when PD168077 was perfused onto
naïve slices (ACSF only: 6.50E-11 ± 3.22E-11 V2 vs. ACSF +
PD168077: 3.89E-11 ± 1.52E-11 V2; n = 4, P = 0.125).
Having identiﬁed the D4R as being responsible for the in-
crease in γ power, we revisited the question of why DA alone
does not produce an increase in power. Indeed, in the presence
of the D1/D5 receptor agonist SKF81297 (1 μM), PD168077
(100 nM) was no longer able to increase power (SKF81297:
1.33E-09 ± 4.98E-10 V2 vs. SKF81297+PD168077: 1.23E-09 ±
4.21E-10 V2; n = 6, P = 0.56). This ﬁnding suggests that D1/D5
receptors oppose the ability of D4Rs to augment γ power
(compare with DA application experiment, Fig. 1 A and E and
Table S1). It also explains why DA increases γ power in the
presence of the D1/D5 receptor blocker SCH23390 (Fig. 1E).
Effects of PD168077 Are Speciﬁc for D4R. To afﬁrm that PD168077
effects on γ oscillations are mediated by D4Rs, we included the
D4R-selective antagonist L-745,870 (500 nM). As shown in Fig. 2
B and D, PD168077 failed to increase γ oscillation power when
slices were perfused with KA and L-745,870 (KA+L-745,870:
3.61E-09± 1.11E-09 V2 vs. KA+L-745,870+PD168077: 3.53E-09±
1.18E-09 V2; n= 6, P= 0.4375). In contrast, the D2/D3-receptor
selective antagonist sulpiride (500 nM) did not affect the re-
sponse to PD168077 (KA+sulpiride: 3.22E-08 ± 0.86E-08 V2 vs.
KA+sulpiride+PD168077: 2.28E-08 ± 0.44E-08 V2; n = 6, P =
0.04; Fig. 2 C and D). Importantly, when used on their own, no
signiﬁcant effects of DA receptor antagonists on KA-induced γ
oscillation power were observed for the D4R antagonist (500 nM
L-745,870: KA: 1.01E-09 ± 5.77E-10 V2 vs. KA+L-745,780:
3.61E-09 ± 1.11E-09 V2; n = 6, P = 0.16) or antagonists selec-
tively targeting either D1/D5 receptors (300 nM SCH23390, KA:
1.77E-09 ± 8.70E-10 V2 vs. SCH23390: 1.99E-09 ± 9.92E-10 V2;
n = 7, P = 0.08) or D2/D3 receptors (500 nM sulpiride, KA:
2.078E-09 ± 9.392 E-10 V2 vs. sulpiride: 2.076E-09 ± 9.397 V2;
n = 7, P = 0.999). Taken together, our results indicate that
activation of D4Rs, but not D2/D3 or D1/D5 receptors, selec-
tively increases the power of hippocampal KA-induced γ oscillations.
D4R Transcripts Are Coexpressed with GAD67-Positive Cells in the
Hippocampus. The expression pattern of D4R protein in the hip-
pocampus is controversial (see refs. 24 and 25 vs. 26). Therefore,
we began by using isotopic in situ hybridization with an antisense
35S-labeled D4R cRNA to investigate receptor expression in the
hippocampus. Emulsion autoradiography with dark-ﬁeld analysis
had to be used to detect the sparse positive cells. D4R transcripts
Fig. 1. Analysis of KA-induced γ oscillations in rat hippocampal slices after
application of DA and selective D1- and D2-type receptor agonists/antagonists.
Representative sample traces (Left) and power spectra (Right) of KA-induced
γ oscillations in rat slices; the color of lines in power spectra correspond to
the type of treatment indicated over each sample trace (Right). (A) DA
(10 μM) was added after the induction of γ oscillations with 100 nM KA
(n = 5). No change was observed with DA. (B) Effect of the D1-type selective
antagonist SCH23390 (300 nM) on KA-induced γ oscillations in presence of
10 μM DA (n = 7). (C) Lack of effect of the D1/D5 receptor agonist SKF81297
(1 μM; n = 14). (D) Lack of effect of the D2/D3 receptor-selective agonist
7-OH-DPAT (100 nM; n = 10). (E) Quantiﬁcation of normalized KA-induced
γ oscillation power in response to the above treatments. Inclusion of the D1/D5
receptor-selective antagonist SCH23390 to the bath solution signiﬁcantly
increased normalized γ oscillation power by 42% (P = 0.013).
Andersson et al. PNAS | August 7, 2012 | vol. 109 | no. 32 | 13119
N
EU
RO
SC
IE
N
CE
accumulate in a few cells in the hippocampus and subiculum (Fig.
3A), presumably corresponding to GABAergic neurons, whereas
principal cells in stratum pyramidale show very low or no signal.
To conﬁrm that the positive cells are GABAergic, double in situ
hybridization (DISH) was performed with the 35S-labeled D4R
cRNA probe and a digoxigenin-labeled probe for GAD67. D4R
transcripts clustered in a subset of GAD67-positive interneurons
(Fig. 3 B–E) in the cornu ammonis and the subiculum; however,
many GABAergic neurons were negative for the receptor. Dou-
bled-labeled GAD67/D4R-expressing cells were observed in the
strata oriens, pyramidale,and radiatum but not in the stratum
lucidum moleculare.
D4R Protein Colocalizes in Cells Positive for the Neuronal Marker
NeuN and for GAD67. Double immunoﬂuorescence histochemistry
(IFH) was used to analyze the cellular expression of the D4R
protein. Of six independent antisera tested (SI Materials and
Methods), an afﬁnity-puriﬁed antibody against the N-terminal 16
amino acids of the rat D4R demonstrated an overlapping dis-
tribution with D4R transcripts (24). Immunoreactivity was sparse
throughout the hippocampus, as exempliﬁed in the two regions
of interest, CA1 (Fig. S2) and CA3, shown in Fig. 3. Double-
labeling with NeuN revealed that D4R immunoreactivity is re-
stricted to neurons (Fig. 3 F–H) and seems to be highest in the
soma and excluded from the nucleus, a subcellular distribution
consistent with reports of other G protein-coupled receptors
(27). Double IFH using a GAD67-speciﬁc antibody showed that
most D4R-positive cells correspond to GABAergic interneurons
(Fig. 3 I–K), consistent with our DISH results (Fig. 3 B–E).
D4R Is Coexpressed with ErbB4 Receptor and PV. Fast-spiking PV+
interneurons play an important role in synchronizing γ oscil-
lations (10), and their enhanced activity is sufﬁcient to generate γ
frequency network activity in vitro (13) and in vivo (14). D4R
immunoreactivity was present in a subset of PV+ interneurons in
CA1 (Fig. 4 A–C) and CA3 (Fig. 4 D–F). Colabeling was most
frequently observed over neuronal cell bodies residing in the stratum
pyramidale and nearby in the strata oriens and radiatum. In these
strata, we found that 71% ± 1.3% of D4R-immunoreative neurons
also express PV (267 of 376 D4R neurons; n= 8 sections from four
rats; mean ± SEM) and that D4R-positive cells represent 25% ±
1.1% of all PV neurons (376 of 1,075 PV+ neurons). That these
D4R-immunoreactive neurons also express PV and reside in the
stratum pyramidale suggests they are fast-spiking GABAergic basket
cells or bistratiﬁed cells as we showed in a recent study (28).
Because ErbB4 receptors modulate KA-induced γ oscillations
in response to NRG-1 and are expressed in ∼50% of PV+
neurons throughout all layers of the cornu ammonis (20), we
investigated whether D4 and ErbB4 receptors are coexpressed.
As shown in Fig. 4 G–I, we found a subset of D4R-immunore-
active neurons that are also ErbB4 positive. On average, 54% ±
0.9% of D4R-positive neurons also express ErbB4 (161 of 296
D4R neurons; n = 8 from four rats; mean ± SEM).
ErbB4 and D4 Receptor Signaling Pathways Converge to Modulate γ
Oscillations. On the basis of the coexpression of D4 and ErbB4
receptors in GABAergic basket cells, the effects of NRG-1 on γ
Fig. 2. Effects of PD168077 on KA-induced γ oscillations are blocked by
a speciﬁc D4R, but not D2/D3 receptor, antagonists. Representative sample
traces (Left) and power spectra (Right) of KA-induced γ oscillations in rat
slices; line colors in power spectra correspond to the type of treatment in-
dicated over each sample trace (Right). (A) The D4R-selective agonist
PD168077 (100 nM) signiﬁcantly increases the power of KA-induced γ oscil-
lations (n = 13). (B) Prior application of the D4R antagonist L-745,870 (500 nM;
n = 6) prevents the PD168077-induced increase in γ oscillation power. (C)
Prior application of the D2/D3 receptor antagonist sulpiride (500 nM; n = 6)
does not prevent the PD168077-induced increase in γ oscillation power.
(D) Summary analysis of normalized data shown in A, B, and C; power of
KA-induced γ oscillations set as 100%.
Fig. 3. D4R mRNA and protein expression in the hippocampus is highest in
GABAgergic interneurons. (A) Representative ISH low-magniﬁcation dark-ﬁeld
images of the hippocampus showing D4R mRNA-expressing neurons. Areas
outlined by rectangles are magniﬁed in A1 and A2 and show accumulation of
grains over sparse cells in the CA1 and the subiculum. (B–E) DISH analysis using
35S-labeled D4R and digoxigenin-labeled GAD67 probes in the CA3 (B and C)
and the subiculum (D and E), revealing colocalization of both transcripts in
a subset of neurons (arrows). (F–K) Double IFH in adult hippocampal sections
for D4R and either the neuronal marker NeuN or GAD67. (F–H) Colocalization
with NeuN shows that D4R immunoﬂuorescence is conﬁned to neurons
located mostly in the strata pyramidale and oriens, the former consistent with
basket cells. (I–K) In CA3, D4R-immunolabeling is observed in GAD67-positive
interneurons (arrows); however, occasionally expression is observed in cells
that are negative or labeled lightly for GAD67. (Scale bars, 100 μm.)
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oscillations (19), and the importance of both receptors for re-
versal of long-term potentiation (18), we reasoned that D4R
activation might be necessary to mediate the effects of NRG-1
on KA-induced γ oscillations. To test this hypothesis, we tested
NRG-1β (2 nM) in the presence of L-745,870. When applied
alone, NRG-1β increased the power of γ oscillations to 266%
(KA: 3.50E-08 ± 0.43 E-08 V2 vs. KA+ NRG-1β: 8.63E-08 ±
1.28E-08 V2; n = 8, P = 0.007; Fig. 5 A and D), an increase that
is signiﬁcantly bigger than the one produced by D4R activation
(Fig. 2 B and E). In contrast, in the presence of L-745,870 (50 nM),
NRG-1β augmented γ oscillation power to only 141% (KA+L-
745,870: 1.78E-08 ± 5.16E-09 V2 vs. KA+L-745,870+NRG-1:
2.51E-08 ± 7.84E-09 V2; n = 8, P = 0.046; Fig. 5 B and D).
The attenuation of the NRG-1 effect on γ oscillation power by
L-745,870 was signiﬁcant (P = 0.0022; Fig. 5D). As indicated
earlier, L-745,870 had no signiﬁcant effect on γ oscillation power
on its own, indicating that NRG-1β effects on γ oscillation power
are dependent on D4R activation.
We also analyzed the effects of the efﬁcacious atypical anti-
psychotic clozapine because it preferentially targets DA recep-
tors, particularly D4Rs (it additionally affects muscarinic and
5HT receptors). As shown in Fig. 5C, clozapine (2 μM) strongly
attenuated the NRG-1β effects on γ oscillation power from
266% to 134% (KA+clozapine: 9.41E-09 ± 3.31 E-09 V2 vs.
KA+clozapine+NRG-1: 7.46E-09 ± 2.82E-09 V2; n = 5, P =
0.04; Fig. 5D), therefore mimicking the effects observed with the
highly selective D4R antagonist L-745,870.
Triple Immunoﬂuorescence Identiﬁes PV+ Interneurons That Coexpress
D4 and ErbB4 Receptors. We used triple IFH for PV, D4R, and
ErbB4 to test the possibility that NRG/ErbB4 and DA/D4R sig-
naling pathways may converge on the same neurons. As shown in
Fig. 5 E–H, we found that D4R- and ErbB4-immunoreactivity
indeed overlap in the soma and proximal dendrites of a subset of
PV+ interneurons in the stratum pyramidale of CA3 that are likely
fast-spiking GABAergic basket or bistratiﬁed cells, on the basis of
their location and our previous results (28). These results are
consistent with the idea that the NRG/ErbB4 and DA/D4R sig-
naling pathways may converge in a subset of interneurons that
regulate γ frequency oscillations and therefore have important
implications for the cellular and network activities altered in
schizophrenia and other psychiatric disorders.
Discussion
Our main ﬁndings are that D4R activation increases KA-induced
γ oscillation power in the hippocampus, that NRG-1-induced
increases in γ oscillation power are signiﬁcantly reduced by
a selective D4R antagonist and by clozapine, and that ErbB4 and
D4 receptors are coexpressed in PV+ interneurons in stratum
pyramidale of CA3. These data are consistent with the idea that
convergence of both signaling pathways in GABAergic inter-
neurons underlies this modulation of γ oscillations. This cross-
Fig. 4. D4 receptors are expressed in parvalbumin- and ErbB4-positive
interneurons. Sample images of double IFH for D4R, and PV or ErbB4. D4R
immunolabeling is observed in PV+ neurons in both CA1 (A–C) and CA3 (D–
F) areas of the hippocampus (arrows). The localization of these PV+ neurons
within or near the pyramidal layer suggests they represent basket cells. (G–I)
A large proportion of D4R-positive cells in CA3 express ErbB4 (arrows). Note
that there are D4R-immunopositive cells in both CA1 and CA3 areas that do
not express PV or ErbB4 (arrowheads); refer to Results for quantiﬁcation in
CA1–CA3 and dentate. (Scale bars, 100 μm.)
Fig. 5. Convergence of ErbB4 and D4R signaling in parvalbumin-positive
interneurons. Representative sample traces (Left) and power spectra (Right)
of KA-induced γ oscillations in rat slices. NRG-1β (2 nM) was tested in com-
bination with (A) KA alone (n = 8), (B) KA and L-745,870 (50 nM; n = 8), or (C)
KA and clozapine (2 μM; n = 5). (D) Summary analysis of normalized data
from A–C. Values for KA treatment are set as 100%. (E–H) Sample images of
triple IFH for D4R, ErbB4 and PV in hippocampal CA3. Overlay image
showing PV+ neurons that also coexpress D4 and ErbB4 receptors (arrows).
(Scale bar, 100 μm.)
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talk, taken together with the fact that polymorphisms in the
NRG-1 and ErbB4 genes are associated with endophenotypes
and risk for schizophrenia, that γ oscillations are altered in
patients with the disorder, that reductions in PV+ interneurons
are reported in postmortem brains of affected individuals, and
that PV+ basket cells are thought to be critical for working
memory and other cognitive functions, should stimulate renewed
attention to drugs modulating D4R function to potentially
ameliorate cognitive deﬁcits in psychiatric disorders.
Differential Function of DA Receptors in the Hippocampus. By using
a combination of antagonists and agonists with speciﬁcity for D1/
D5, D2/D3, and D4 receptors, we revealed a selective effect of
D4R activation on KA-induced γ oscillation power. In an earlier
study (29), D1/D5 receptor activation produced a decrease in
carbachol-induced γ oscillations. We, in contrast, did not ﬁnd
that D1/D5 receptor activation decreases KA-induced γ oscilla-
tion power. On the basis of our observations (Figs. 1 and 2), we
suggest instead that D1/D5 receptor activity can counteract the
D4R-mediated increase in γ oscillation power, consistent with
studies showing bidirectional effects of DA (22, 23). Future
studies will be necessary to determine whether the opposing
actions of D1/D5 and D4 receptor activity in the hippocampus
result from their differential cellular expression in glutamatergic
(16) and GABAergic interneurons (Fig. 3) (24, 25), respectively,
or from the opposing coupling of these receptors to different
downstream signaling pathways.
Signiﬁcance of ErbB4 and D4 Receptor Expression in PV+ GABAergic
Interneurons for γ Oscillations. Alterations in DA, glutamate, and
GABA neurotransmission, and in particular the function of fast-
spiking PV+ interneurons, have been implicated in the observed
deﬁcits in neuronal network function that may account for
reductions in cortical and hippocampal γ oscillation power and
for functional disconnectivity in neural circuits observed in
schizophrenia (2, 15, 30). A recent optogenetic study in the
frontal cortex of mice supports the hypothesis that the excitatory/
inhibitory balance critically regulates cortical network function
and behaviors associated with psychiatric disorders (31), and that
this balance can be modulated by DA (15).
Expression of ErbB4 receptors is restricted to ∼50% of
GABAergic PV+ interneurons in the rodent hippocampus (20),
whereas in the frontal cortex most ErbB4-positive interneurons
also express PV (21). Interestingly, in ErbB4 null mice, en-
hancement of KA-induced γ oscillation power by NRG-1 is ab-
sent, and there is an ∼60% reduction in endogenous γ oscillation
power that coincides with a loss of PV+ interneurons (19). The
observation that D4Rs are expressed in a subset of ErbB4-
expressing PV+ interneurons in CA1 and CA3 suggests that
NRG/ErbB4 and D4R signaling pathways converge on the same
fast-spiking basket cells to regulate γ oscillation power. Although
overlap between D4 and ErbB4 receptors is partial—possibly
accounting for the different efﬁcacies between D4R agonists and
NRG1 to increase γ oscillation power—it should be emphasized
that D4R activity is critical for NRG1 to exert its full effect on γ
oscillation (Fig. 5).
What are the potential mechanisms that mediate the effects of
ErbB4 and D4Rs on KA-induced γ oscillations? Both signaling
pathways acutely regulate NMDA and AMPA receptor trafﬁck-
ing (18, 32), and ErbB4Rs are closely associated with gluta-
matergic synapses on PV+ interneurons (17). Even though
NMDA and AMPA receptors are not necessary for some types of
γ oscillations (8), γ power can be increased through regulation of
AMPA and/or NMDA receptors in PV+ interneurons by mod-
ulating excitatory/inhibitory balance and optimizing phase-syn-
chronization of action potential discharges (31). Likewise,
regulation of voltage-gated ion channels such as Kv7 can produce
changes in γ oscillation power by regulating neuronal γ phase-
synchrony (8, 9). GABAA receptors are another potential
downstream target of D4Rs, which are expressed in both gluta-
matergic and inhibitory neurons in the PFC (24, 25). Perfusion of
acute PFC slices and cultured neurons with PD168077 (30 μM)
was reported to decrease surface expression of GABAA receptors
(33). Because GABAA receptor modulation affects γ oscillation
frequency (8), and we did not observe any such changes with
PD168077, we lack evidence for GABAA receptor involvement.
Although our results clearly show that NRG’s effects on γ os-
cillation power require the activity of ErbB4 and D4 receptors,
additional studies will be necessary to understand the underlying
ionic currents regulated by both receptors in PV+ interneurons.
Psychiatric Disorders, γ Oscillations, and the Potential Use of D4R-
Targeting Drugs to Modulate Cognitive Functions. Our studies
showing that increases in γ oscillation power in response to
NRG1 require the activity of ErbB4 and D4 receptors suggests an
important nexus where genes and network activity associated
with psychiatric disorders intersect in PV+ neurons. Genetic
variants of NRG1 and ERBB4 constitute risk factors for schizo-
phrenia (17) and associated endophenotypes (34), and the
DRD4-7R functional variant is a risk factor for ADHD (35) and
is associated with deﬁcits in attention, working memory, and γ
band activity (36). These results suggest that alterations in D4R
function may underlie endophenotypes shared by both disorders.
Importantly, mice harboring targeted mutations of NRG-1 and
ErbB4 exhibit behavioral deﬁcits (including working memory)
similar to other rodent models for schizophrenia (37, 38), and
NRG-1 hypomorphs respond positively to clozapine administra-
tion (37), suggesting that D4R modulation underlies these
behaviors. Pharmacological and genetic studies targeting D4Rs in
primates and rodents also support a critical role of the receptor
in cognitive processes (36, 39, 40). Therefore, our prior (18) and
present studies on the importance of the NRG/ErbB and D4R
signaling for synaptic plasticity and γ oscillations, respectively,
suggest that functional interactions between both signaling
pathways may be critically important for cognitive functions.
Although ﬁrst (“typical”) and second (“atypical”) generation
antipsychotics have generally demonstrated efﬁcacy to treat
positive symptoms of schizophrenia, in most part, they have
failed to improve symptoms that involve affect and social func-
tion, as well as working memory and other cognitive functions
(41). The important association of γ oscillations with attention,
working memory, and other cognitive functions (1), and their
perturbation in numerous psychiatric disorders (2, 3, 42, 43),
underscores the potential therapeutic value of targeting net-
works that generate and regulate γ oscillations. We propose, on
the basis of the functional properties and expression of ErbB4
and D4Rs in PV+ interneurons in the dorsal lateral prefrontal
cortex (21, 25) and hippocampus (this study), as well as their
effects on KA-induced γ oscillations and plasticity (18, 19), that
these receptors are well situated to modulate network activity
that impacts cognition. The fact that D4R-speciﬁc antagonists
were found to be ineffective as antipsychotics for the treatment of
schizophrenia (44, 45) does not negate the potential use of D4R
targeting drugs to treat cognitive deﬁcits, as suggested by studies
in primates and rodents (39, 40, 46, 47). The colocalization of D4
and ErbB4 receptors on PV+ interneurons, activity of which is
critically important for regulating excitatory/inhibitory balance
and cognitive functions (31), perhaps by optimizing “signal-to-
noise” ratio of cortical microcircuits (15), makes these receptor
systems attractive targets for modulating network activities that
underlie cognition.
Materials and Methods
Animals. Procedures for the care and use of laboratory animals were approved
and according to the Stockholms Norra Djurförsöksetiska Nämnd, Sweden,
and the National Institutes of Health and Texas A&M University.
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Electrophysiology. Local ﬁeld potential recordings from horizontal Sprague-
Dawley rat hippocampal slices (300 μm) in CA3 were performed at 32 °C in
a submerged recording chamber (SI Materials and Methods), essentially as
described previously (19). Drugs were obtained from Sigma-Aldrich (kainic
acid), R&D Systems (NRG-1β), and Tocris (all other drugs). Fast Fourier trans-
forms for power spectra were computed from 60-s traces and power values
obtained by integrating power spectra between 20 and 80 Hz using Kaleida-
Graph (Synergy Software). Statistical calculations were carried out using
GraphPad Prism. Data are reported as mean ± SEM, as well as in normalized
form ± SEM where normalization for the KA-only value was set to 100%.
DISH and IFH. DISH experiments were performed as previously reported (48)
using C57Bl6/J mouse brain sagittal cryostat sections (20 μm) hybridized with
S35-CTP- and digoxigenin-labeled D4R and GAD67 cRNA probes, respectively.
After alkaline phosphatase treatment for Dig, slides were exposed for 4 wk
for autoradiography. Double and triple immunoﬂuorescence histochemistry
experiments were essentially as previously described (20) using an afﬁnity-
puriﬁed N-terminal rabbit antibody (24); speciﬁcity was determined by
immunoﬂuorescence analysis of cultured hippocampal neurons transfected
with D1-D5 receptor cDNA expression vectors (SI Materials and Methods).
Multiple IFH was performed in 3-wk-old rat vibratome coronal sections
(50 μm) using antibodies for D4R (2 μg/mL), GAD67 (1:5,000; mouse mAb
5406; Millipore), PV (1:6,000; mAb P19; Sigma), and ErbB4 (3 μg/mL; mAb-77;
ThermoScientiﬁc). Confocal immunoﬂuorescence images were obtained
with 20× and 63× oil objectives.
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